VeSpAR: Comparing Vessel-Sparing Anastomotic Repair and Transecting Anastomotic Repair in Isolated Short Bulbar Strictures.

Sponsor
University Hospital, Ghent (Other)
Overall Status
Recruiting
CT.gov ID
NCT03572348
Collaborator
(none)
100
13
2
63.1
7.7
0.1

Study Details

Study Description

Brief Summary

The investigators want to verify whether the surgical outcome of vessel-sparing anastomotic repair in isolated short bulbar urethral strictures is not inferior to the surgical outcome of transecting anastomotic repair. Furthermore, the investigators compare the functional outcome of both techniques verifying if there is less erectile dysfunction after vessel-sparing anastomotic repair than after transecting anastomotic repair.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Transecting anastomotic repair (tAR)
  • Procedure: Vessel-sparing anastomotic repair (vsAR)
N/A

Detailed Description

A randomized controlled trial comparing vessel-sparing anastomotic repair (vsAR) and transecting anastomotic repair (tAR) in isolated short bulbar urethral strictures (maximum 3 centimeter) for both surgical and functional outcome, to demonstrate that vsAR is not inferior to tAR regarding the surgical outcome, and to demonstrate a benefit for vsAR over tAR regarding postoperative erectile function.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Prospective, interventional, multicentric, single-blinded, randomized, controlled, non-inferiority, phase II trialProspective, interventional, multicentric, single-blinded, randomized, controlled, non-inferiority, phase II trial
Masking:
Single (Participant)
Masking Description:
Patients will be randomized using software in a 1:1 ratio in either the vessel-sparing group or the transecting group. Randomisation will be stratified per participating center and single blinded; double blindation is impossible as the surgeon has to know which technique to perform.
Primary Purpose:
Treatment
Official Title:
VeSpAR: A Randomized Controlled Trial Comparing Vessel-Sparing Anastomotic Repair and Transecting Anastomotic Repair in Isolated Short Bulbar Urethral Strictures
Actual Study Start Date :
Sep 26, 2018
Anticipated Primary Completion Date :
Dec 21, 2022
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Transecting anastomotic repair (tAR)

Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.

Procedure: Transecting anastomotic repair (tAR)
Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.

Active Comparator: Vessel-sparing anastomotic repair (vsAR)

Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.

Procedure: Vessel-sparing anastomotic repair (vsAR)
Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.

Outcome Measures

Primary Outcome Measures

  1. FFS at 24 months [24 months]

    Failure-free survival at 24 months. Surgical failure is defined as urethroscopic evidence of stricture recurrence, impossible to pass with a 16Fr silicone urethral catheter, independent of whether the stricture is treated or not.

Secondary Outcome Measures

  1. FFS at 3 and 12 months [3 and 12 months]

    Failure-free survival at 3 and 12 months. Surgical failure is defined as urethroscopic evidence of stricture recurrence, impossible to pass with a 16Fr silicone urethral catheter, independent of whether the stricture is treated or not.

  2. Erectile function [3, 12, and 24 months]

    Erectile function score assessed by the International Index of Erectile Function (IIEF-5) questionnaire

  3. Ejaculatory function [3, 12, and 24 months]

    Ejaculatory function score assessed by the Male Sexual Health Questionnaire - Ejaculatory Dysfunction short form (MSHQ-EjD short form)

  4. Voiding function [3, 12, and 24 months]

    Lower Urinary Tract symptoms assessed by the Peeling's voiding picture.

  5. Lower Urinary Tract symptoms [3, 12, and 24 months]

    Lower Urinary Tract symptoms assessed by the International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptoms module (ICIQ-MLUTS)

  6. Urinary incontinence [3, 12, and 24 months]

    Urinary incontinence assessed by the International Consultation on Incontinence Questionnaire - Urinary Incontinence short form (ICIQ-UI)

  7. Maximum flow rate [3, 12, and 24 months]

    Qmax assessed using uroflowmetry

  8. Residual urinary volumes [3, 12, and 24 months]

    Residual urinary volumes examined by suprapubic ultrasonic measurement after voiding

  9. Quality of life (EQ-5D-3L) [3, 12, and 24 months]

    QoL scored by the EQ-5D-3L questionnaire

  10. Quality of life (EQ-VAS) [3, 12, and 24 months]

    QoL scored by the EQ visual analogue scale (EQ-VAS)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Voluntary signed written informed consent (according to the rules of Good Clinical Practice and national regulations)

  • Male

  • Age >= 18 years

  • Fit for operation, based on the surgeon's expert opinion

  • Isolated short (=< 3cm) bulbar urethral stricture confirmed by preoperative retrograde urethrography (RUG), voiding cysto-urethrography (VCUG), cystoscopy, ultrasonography or a combination of investigations

  • Unique urethral stricture

  • Urethral stricture =< 3 cm

  • Urethral stricture at the bulbar segment

  • Patient declares that it will be possible for him to attend the follow-up consultation

Exclusion Criteria:
  • Absence of signed written informed consent

  • Age <18 years

  • Female patients

  • Transgender patients

  • Patients unfit for operation

  • Concomitant urethral strictures at other urethral locations (penile urethra, membranous urethra, prostatic urethra, bladder neck)

  • Urethral strictures exceeding 3 cm

  • A unique urethral stricture at other urethral locations (penile urethra, membranous urethra, prostatic urethra, bladder neck)

  • Lichen Sclerosus related strictures

  • Strictures after failed hypospadias repair

  • Patients with neurogenic bladder

  • Shift of technique to augmented urethroplasty due to any circumstance

  • History of pelvic radiation therapy

  • Active treatment to enhance erectile function (such as PDE5-inhibitors and intracavernous injections) at the moment of prescreening for inclusion in this trial

  • Any condition or situation, which, in the investigator's opinion, puts the patient at significant risk, could confound the study results, or may interfere significantly with the patient's participation in the study

  • Patient declares that it will be impossible for him to attend the follow-up consultations

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Urology, SUNY Upstate Medical University Syracuse New York United States 13210
2 Department of Urology, Eastern Virginia Medical School Norfolk Virginia United States 23507-1912
3 Department of Urology, Centro de Educación Médica e Investigaciones Clínicas Buenos Aires Argentina
4 Department of Urology, Hospital Italiano de Buenos Aires Buenos Aires Argentina
5 Dept. of Urology, Ghent University Hospital Ghent Belgium 9000
6 Dept. of Urology, University Hospital Leuven Leuven Belgium
7 Department of Urology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital Shanghai China
8 Centro de Uretra Las Alamedas Ciudad de mexico Mexico
9 Department of Urology, Hospital San José Tecnológico de Monterrey, Universidad de Monterrey Monterrey Mexico
10 Department of Urology, Hospital de Santa María, Universidad de Lisboa Lisboa Portugal
11 Department of Urology, Departamento Clínico, Facultad de Ciencias Biomédicas, Universidad Europea de Madrid, Hospital Universitario de Getafe Madrid Spain
12 Dept. of Urology, Hospital Univ. de Valdecilla Santander Spain
13 Department of Urology, University College London Hospital London United Kingdom

Sponsors and Collaborators

  • University Hospital, Ghent

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University Hospital, Ghent
ClinicalTrials.gov Identifier:
NCT03572348
Other Study ID Numbers:
  • UZG-U2018/01
First Posted:
Jun 28, 2018
Last Update Posted:
Mar 29, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Ghent
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 29, 2022